Pharmacometabolomics of Statin Response

Statins reduce risk of cardiovascular disease (CVD) by decreasing plasma low‐density lipoprotein (LDL) concentrations, as well as reducing inflammation and improving endothelial function. Despite their documented efficacy, there is considerable interindividual variation in effects of statins on CVD...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2013-11, Vol.94 (5), p.562-565
Main Authors: Krauss, R M, Zhu, H, Kaddurah-Daouk, R
Format: Article
Language:English
Subjects:
Bile Acids and Salts - metabolism
Biological and medical sciences
Chromatography, Gas
Gas Chromatography-Mass Spectrometry
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Lipid Metabolism - drug effects
Lipids - blood
Lipoproteins, LDL - metabolism
Medical sciences
Metabolomics - methods
Pharmacology. Drug treatments
Sterols - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statins reduce risk of cardiovascular disease (CVD) by decreasing plasma low‐density lipoprotein (LDL) concentrations, as well as reducing inflammation and improving endothelial function. Despite their documented efficacy, there is considerable interindividual variation in effects of statins on CVD biomarkers. In the studies summarized here, we used complementary metabolomics platforms to define global effects of a statin (simvastatin) on metabolism and to identify markers indicative of mechanisms that contribute to variation in plasma LDL response to statin treatment. Clinical Pharmacology & Therapeutics (2013); 94 5, 562–565. doi:10.1038/clpt.2013.164
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2013.164